Pacira BioSciences (PCRX)

PCRX Pain Management

BiotechSign Signal Grade

F
Signal Grade
7.9/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
24
Clinical Activity
0
Short Interest
70

Pipeline Overview

Therapeutic Focus
Pain Managementsrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
1 Phase 4
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov

Dilution Risk

LOW DILUTION RISK
24/100
Dilution Score
40Warrant Risk
40Convertible Risk
37Offering Ability

Dilution score: 24/100 (LOW), cash runway not available

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

22.46%
Float Shorted
13.0
Days to Cover
HIGH
Squeeze Risk
+3.2%
SI Change
STABLE
Trend
7,561,153
Shares Short

Short interest: 22.46% of float, squeeze risk: HIGH

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Pacira BioSciences.

Full PCRX Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.